The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LTRN | +15.89% | -81.72% | -28.82% | -77% |
| S&P | +15.66% | +86.6% | +13.29% | +130% |
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$4.10K | 91.4% |
| Market Cap | $46.98M | 18.9% |
| Market Cap / Employee | $1.96M | 0.0% |
| Employees | 24 | 14.3% |
| Net Income | -$4,177.42K | 7.3% |
| EBITDA | -$4,345.70K | 15.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $8.39M | 3.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $93.95K | -52.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -86.16% | -37.2% |
| Return On Invested Capital | -41.87% | 31.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,572.54K | 18.1% |
| Operating Free Cash Flow | -$4,571.98K | 18.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.29 | 1.80 | 2.03 | 3.75 | 193.49% |
| Price to Tangible Book Value | 1.29 | 1.80 | 2.03 | 3.75 | 193.49% |
| Enterprise Value to EBITDA | -1.82 | -3.91 | -3.94 | -8.02 | 250.64% |
| Return on Equity | -66.9% | -75.7% | -88.6% | -104.6% | 97.22% |
| Total Debt | $243.66K | $194.93K | $145.04K | $93.95K | -67.74% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
